It has been widely accepted that pre-treatment prostate-specific antigen (PSA) below 10 ng/mL, a biopsy Gleason score of 6 or less, and clinical stage T1c or T2a identify low-risk PCa [2]. The gene discussed is KLK3; the disease is posterior cortical atrophy.